Rand Issues Commentary: GLP-1 Agonists in Perimenopause - Unique Risks and Potential Opportunities
August 07, 2025
August 07, 2025
SANTA MONICA, California, Aug. 7 -- Rand issued the following commentary on Aug. 6, 2025:
* * *
GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities
By Katherine M. Rancano and Shannon D. Donofry
Glucagon-like-peptide-1 receptor agonists (GLP-1s), including medications like Ozempic(R) and Zepbound(R), have transformed weight management and treatment of chronic disease.
But while GLP-1s are commonly used by peri . . .
* * *
GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities
By Katherine M. Rancano and Shannon D. Donofry
Glucagon-like-peptide-1 receptor agonists (GLP-1s), including medications like Ozempic(R) and Zepbound(R), have transformed weight management and treatment of chronic disease.
But while GLP-1s are commonly used by peri . . .